Amy­lyx’s ALS dis­ap­point­ment; Lil­ly's Alzheimer's de­lay; Bay­er stays put; No­vo Nordisk's GLP-1 streak; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

End­points News is once again look­ing to high­light LGBTQ+ lead­ers in bio­phar­ma across a va­ri­ety of roles. I en­cour­age you to read Kyle LaHu­cik’s heart­felt note on why we’re con­tin­u­ing this spe­cial re­port for a third year. It al­so de­tails how you can nom­i­nate some­one for the re­port.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER